University of Bristol Psychopharmacology Unit, School of Medical Sciences, University Walk, Bristol BS8 1 TD, UK.
J Psychopharmacol. 1995 Jan;9(2):137-41. doi: 10.1177/026988119500900208.
The selective serotonin re-uptake inhibitors (SSRIs) are increasingly being used to treat depression and anxiety disorders. Gastrointestinal (GI) symptoms are the main side effects, probably resulting from the stimulation of central or peripheral 5-HT receptors. The present double-blind, placebo-controlled study was undertaken to see if the GI side effects of fluvoxamine could be attenuated by the co-administration of the 5-HT(3) antagonist ondansetron. The results demonstrate that, in volunteers, a single 100 mg oral dose of fluvoxamine can produce GI symptoms. Co-administration of ondansetron significantly reduced peak nausea and GI side effects, compared with placebo.
选择性 5-羟色胺再摄取抑制剂（SSRIs）越来越多地被用于治疗抑郁症和焦虑症。胃肠道（GI）症状是主要的副作用，可能是由于中枢或外周 5-HT 受体的刺激所致。本双盲、安慰剂对照研究旨在观察 5-HT3 拮抗剂昂丹司琼是否能减轻氟伏沙明的胃肠道副作用。结果表明，在志愿者中，单次口服 100mg 氟伏沙明可产生胃肠道症状。与安慰剂相比，昂丹司琼的联合应用显著减轻了恶心和胃肠道副作用的峰值。
